[Form 4] Aptevo Therapeutics Inc Insider Trading Activity

Rhea-AI Filing Summary

Aptevo Therapeutics' President and CEO, Marvin L. White, was granted 30,000 Restricted Stock Units (RSUs) with a transaction date of 08/06/2025. The RSUs convert one-for-one into common stock and are reported as direct beneficial ownership. The awards vest in full on the first anniversary of the grant, at which time 30,000 common shares become issuable.

Positive

• 30,000 RSUs granted to the President and CEO, increasing direct beneficial ownership by 30,000 underlying shares
• RSUs convert one-for-one into common stock, providing a clear conversion metric
• Vesting in full after one year establishes a defined, time-based vesting schedule

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: A 30,000-RSU grant to the CEO increases direct beneficial ownership; vesting is time-based and occurs one year after grant.

The Form 4 documents a time-based equity award of 30,000 Restricted Stock Units to Marvin L. White, who is identified as both President and CEO and a director. The RSUs convert on a one-for-one basis into common stock and are recorded as direct ownership, with full vesting on the first anniversary of the grant date. Based solely on the form, this is a standard executive equity grant reported under Section 16 rules; the filing does not provide information on total outstanding shares or the award's percentage dilution.

Compensation Analyst

TL;DR: The award is a time-vested RSU grant of 30,000 shares to the CEO, vesting in one year and converting 1:1 to common stock.

The disclosure shows 30,000 RSUs were acquired on 08/06/2025 and are exercisable into 30,000 common shares at a one-for-one conversion. The RSUs are reported as directly beneficially owned and vest in full on the first anniversary of grant. The Form does not disclose grant rationale, performance conditions, or the company's total share count, limiting assessment of materiality from this document alone.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

White Marvin L

(Last) (First) (Middle)

2401 4TH AVENUE

1,050

(Street)

SEATTLE WA 98121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aptevo Therapeutics Inc. [ APVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	08/06/2025		A		30,000		(2)	(2)	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.

2. The RSUs vest in full on the first anniversary of the date of grant.

	/s/ SoYoung Kwon, Attorney-in-Fact	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did APVO report in this Form 4?

The Form 4 reports a grant of 30,000 Restricted Stock Units (RSUs) to Marvin L. White with a transaction date of 08/06/2025.

Who is the reporting person on the APVO Form 4?

The reporting person is Marvin L. White, identified as President and CEO and as a director of Aptevo Therapeutics.

How do the RSUs convert and when do they vest?

The RSUs convert one-for-one into common stock and the RSUs vest in full on the first anniversary of the grant date.

How many shares are beneficially owned after the transaction and in what form?

The Form indicates 30,000 underlying common shares are beneficially owned following the reported transaction and are held in direct form.

Was any purchase price reported for the RSUs?

The table shows a price of $0 associated with the reported RSUs in the filing.

Who signed the Form 4?

The Form is signed by SoYoung Kwon, Attorney-in-Fact as the signing representative for the reporting person.